GlycoMimetics, Inc. Announces Presentation Of Data On Rivipansel (GMI-1070) In Combination With Current FDA-Approved Treatment For Sickle Cell Disease

GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that data for its lead clinical drug candidate, rivipansel (GMI-1070), was highlighted via one oral presentation and one poster at the 8th Annual Sickle Cell Disease Research and Educational Symposium and 37th National Sickle Cell Disease Scientific Meeting, held April 11-14, 2014, at the InterContinental Miami.

Help employers find you! Check out all the jobs and post your resume.